Kailera Therapeutics Inc. (KLRA) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Kailera Therapeutics Inc. (KLRA) slipped -0.07% to $13.41, trading at 20% of its 52-week range ($9.76 – $28.23). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-prolif
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KLRA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KLRA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Kailera Therapeutics Inc. (KLRA) ranks #342 by composite RQD confidence (50/100, grade D) and #282 by equity capitalization ($1.74B). Within this direct 5-issuer industry benchmark cohort, KLRA leads on earnings valuation at N/A trailing P/E, while STOK leads on capital efficiency and profitability with -6.1% ROIC and — gross margin. STOK currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with KLRA at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KLRA
ACTIVE
Kailera Therapeutics Inc. | D | 50/100 | — | — | — | -0.07% | $1.74B | Benchmark Subject |
| QURE uniQure N.V. | D+ | 52/100 | — | — | -35.0% | +1.32% | $1.75B | /qure-vs-klra → |
| NBTX Nanobiotix S.A. | D+ | 52/100 | — | — | — | -0.53% | $1.72B | /nbtx-vs-klra → |
| STOK Stoke Therapeutics Inc. | C- | 59/100 | — | — | -6.1% | -0.23% | $1.70B | /stok-vs-klra → |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 37/100 | — | — | -35.0% | -0.73% | $1.69B | /cmps-vs-klra → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kailera Therapeutics Inc. (KLRA) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KLRA closed FY2025 with $692.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $692.3M | — |
As of 2026-11-01, Kailera Therapeutics Inc. (NASDAQ: KLRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $13.41 (-0.07% 1D, market cap $1.74B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KLRA ranks #342 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KLRA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, QURE (uniQure N.V.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B) and NBTX (Nanobiotix S.A.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.72B). Among the 5-stock peer group, KLRA leads on earnings multiple (N/A) while STOK leads on capital efficiency (-6.1% ROIC).
Per KLRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002096997), Kailera Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $692.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KLRA last traded at $13.41 (-0.07% on volume of 1,044,500 shares), positioning the stock +0.90% above its 50-day simple moving average ($13.29) and -25.42% below its 200-day simple moving average ($17.98). Across its 52-week range of $9.76 to $28.23, KLRA sits at the 19.8% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.73 to $15.09).
Why KLRA Stock slipped -0.07% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.